Sermorelin Side Effects: What the Label and Trials Recorded

The short answer: in the studies that exist, sermorelin's most common side effects were transient facial flushing and pain at the injection site¹. Larger problems such as fluid retention, joint pain and blood-sugar changes belong to the growth-hormone pathway it switches on, and they are documented far better for growth hormone itself than for sermorelin⁹. The catch is where the safety record comes from: mostly children with growth hormone deficiency in the 1990s, plus a handful of small, short studies in older adults. Nobody has run a large, long placebo-controlled trial of sermorelin in the healthy adults who buy it today.

So the honest answer has two parts. Short-term, at studied doses, sermorelin looked well tolerated. Long-term, in healthy adults, the record is close to empty.

What the Geref Era Recorded

Sermorelin was a real FDA-approved drug, sold by EMD Serono as Geref. One form was approved in December 1990 as a diagnostic test of the pituitary's ability to release growth hormone, and the other in September 1997 for treating children with idiopathic growth hormone deficiency³⁴.

The pediatric treatment data are the backbone of everything known about its safety. In the main multicenter study, 110 previously untreated children took 30 micrograms per kilogram at bedtime for up to a year. The investigators reported no adverse changes in routine blood chemistry or hormones, no change in fasting glucose, no excessive rise in IGF-1, and concluded the drug was well tolerated². A later review of the whole program named transient facial flushing and injection-site pain as the most commonly reported adverse events, after both single intravenous doses and repeated daily injections¹.

Two caveats keep that record in proportion. These were children with a diagnosed hormone deficiency, not adults with normal pituitaries looking for an anti-aging effect. And the doses were weight-based for small bodies over months, not the multi-year adult protocols sold now.

Why Geref Disappeared (It Was Not Safety)

In 2008 EMD Serono told FDA it was discontinuing both Geref products, in letters dated July 11 and December 2³. In March 2013 FDA published a formal determination in the Federal Register that both had not been withdrawn from sale for reasons of safety or effectiveness³. A 2006 commentary had already described the commercial reason: sermorelin could not compete with recombinant growth hormone in children and was withdrawn by its maker¹¹.

That determination matters for two reasons. It is the record that lets compounding pharmacies treat sermorelin acetate as a component of a once-approved drug, which is why it is sold by prescription today; the cost side of that story is in sermorelin cost. And it means no safety signal ended the product. It does not mean the compounded product you buy now was tested to the same standard, which is a separate question covered below.

What the Adult Studies Found

The adult evidence is small, short and mostly in older men. It still answers some practical questions.

• •Two weeks, twice daily, older men. Ten healthy men around 68 years old took 0.5 mg and 1 mg of GHRH(1-29) twice daily for 14 days each. Growth hormone and IGF-1 rose to young-adult levels on the higher dose, and fasting glucose, urinary C-peptide, blood pressure and routine chemistry and blood counts did not change⁵.
• •Six weeks, nightly, older men. Eleven men aged 64 to 76 self-injected 2 mg of GHRH(1-29) every night for six weeks. Nighttime growth hormone rose, and the authors reported no significant adverse effects⁶.
• •Four months, nightly, men and women. Nineteen adults aged 55 to 71 used a closely related GHRH(1-29) analog for 16 weeks. The only adverse effect reported was a transient rise in blood lipids that resolved by the end of the study⁷.

The sleep claim deserves its own line, because "better sleep" is a selling point. In a randomized study with sleep EEG, systemic GHRH impaired sleep in healthy young women⁸. If your sleep gets worse after starting, that is a recorded effect of the pathway, not something to push through. More in sermorelin dosage.

Water Retention, Joint Pain and Blood Sugar

These are the side effects people search for most, and they are real, but the strongest evidence for them comes from growth hormone rather than sermorelin.

A systematic review of growth hormone in healthy older adults found that treated people were significantly more likely to develop soft-tissue swelling, joint pain, carpal tunnel syndrome and breast tissue growth in men, and somewhat more likely to develop diabetes or impaired fasting glucose⁹. In young, fit adults, growth hormone also caused more swelling and fatigue¹⁴.

Sermorelin raises growth hormone indirectly, and the body's own brakes still operate, which is the main argument for why its effects should be milder¹¹. The closest labeled relative shows the same pattern at a real dose. Tesamorelin, the only GHRH analog with a current US label, lists fluid retention (swelling, joint pain, carpal tunnel), glucose intolerance, injection-site reactions in 25% of patients against 14% on placebo, and hypersensitivity reactions in 4%¹⁰. Its label also tells prescribers to monitor IGF-1 and glucose¹⁰. Sermorelin has no such label, so those checks only happen if your prescriber orders them. The full tesamorelin picture is in tesamorelin side effects.

How often? Nobody can honestly put a percentage on swelling or headache with today's adult sermorelin protocols. Any precise figure you see online for those is not traceable to a trial in healthy adults.

IGF-1 Is the Number to Watch

Most of the growth-hormone side effects track one blood marker, IGF-1, which the liver makes in response to growth hormone. It is how prescribers see whether sermorelin is doing anything, and it is also the early warning that it is doing too much.

The studies show both sides. In the pediatric program, IGF-1 did not rise excessively². In older men on twice-daily injections, IGF-1 climbed back to young-adult levels within two weeks⁵, which is the intended effect and also the point where the growth-hormone side effects above become relevant. The tesamorelin label puts a number on "too much": it tells prescribers to monitor IGF-1 and to consider stopping in patients with persistent elevations, giving more than 3 standard deviations above normal as the example¹⁰. Ask for a baseline IGF-1 before your first injection and a repeat once you are on a steady dose.

Symptoms That Mean Stop and Call

Most injection-site soreness and flushing fade on their own. Rotating injection sites is the standard advice for reducing site reactions, and it is written into the tesamorelin label for exactly that reason¹⁰. These are different, and worth a call to the prescriber before the next dose:

• •New swelling in the hands, feet or ankles, or rings that suddenly feel tight.
• •Numbness or tingling in the fingers, especially at night, which can be early carpal tunnel.
• •Joint or muscle pain that started after sermorelin did.
• •Unusual thirst or frequent urination, which can signal rising blood sugar.
• •Hives, a spreading rash, or flushing with trouble breathing. The tesamorelin label lists itching, redness, flushing, hives and rash as hypersensitivity reactions and tells patients to seek prompt medical attention and stop treatment¹⁰. Trouble breathing is an emergency.

Who Should Not Take It

With no current US label, there is no official contraindication list for sermorelin. The sensible guide is the growth-hormone axis itself and the label of its closest relative. Tesamorelin is contraindicated in active cancer, in pregnancy, in people with disruption of the hypothalamic-pituitary axis, and in people allergic to the drug, and it tells prescribers to discontinue it if a cancer recurs¹⁰. Growth hormone's link to cell growth is the reason cancer history comes first on that list. Raise any of the following before a first prescription:

• •active cancer, or a cancer that is not fully treated
• •pregnancy, or trying to conceive
• •diabetes or prediabetes
• •a pituitary or hypothalamic condition
• •a past reaction to sermorelin or any of its excipients

Compounded Today vs Geref Then

Everything sold now is compounded. Compounded drugs are not FDA-approved, and FDA does not review them for safety, effectiveness or quality before they are sold¹². In practice the safety record above was earned by a manufactured, labeled product, and today's vials, troches and nasal sprays borrow it. The injection is at least the same route the trials used. Troches, sprays and dissolving tablets have no published safety data of their own at all.

The seller matters too, mostly through what it tells you and when. CoreAge Rx keeps one sermorelin price as the dose rises. Eden's first-month sermorelin price sits on top of a required membership. Strut Health's $119 exists only on auto-refill. HealthRX prints its whole price ladder but takes payment before the clinical review, and RNK Health's lowest rate means paying for six months at once. Compare the rest on the sermorelin provider board.

What to Ask the Prescriber

A good prescriber will welcome these questions. If the answers are vague, that tells you something about the follow-up you will get.

Sport

Sermorelin is named on the World Anti-Doping Agency's 2026 Prohibited List, under growth hormone releasing factors, prohibited at all times¹³. Any tested athlete should treat that as final; see does sermorelin help athletes.

Bottom Line

Sermorelin's recorded side effects are mostly mild and short-lived: flushing and sore injection sites in the trials, plus a lipid blip in one adult study. The serious-sounding effects, swelling, joint pain, carpal tunnel and blood sugar, are real risks of raising growth hormone and are well documented for the hormone itself and for the one labeled GHRH analog. What is missing is the long-term adult trial that would tell you how often they happen with today's protocols. Start with a prescriber who will check IGF-1 and glucose, and stop and report any new swelling, numb fingers or worse sleep. This page is educational, not medical advice.